Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Stock Has Consensus Target Price of $10.00

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $10.00.

A number of research analysts have recently weighed in on the company. Weiss Ratings lowered Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, November 3rd. UBS Group reaffirmed a “buy” rating on shares of Autolus Therapeutics in a report on Wednesday. Wall Street Zen upgraded Autolus Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. Finally, HC Wainwright reiterated a “buy” rating on shares of Autolus Therapeutics in a research report on Wednesday.

Check Out Our Latest Research Report on Autolus Therapeutics

Autolus Therapeutics Stock Performance

AUTL opened at $1.17 on Monday. The company has a market cap of $311.62 million, a P/E ratio of -1.21 and a beta of 2.32. The company has a quick ratio of 3.36, a current ratio of 3.72 and a debt-to-equity ratio of 5.25. The firm’s 50-day moving average price is $1.70 and its 200-day moving average price is $1.66. Autolus Therapeutics has a 52-week low of $1.12 and a 52-week high of $2.58.

Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.21). Autolus Therapeutics had a negative net margin of 186.37% and a negative return on equity of 263.25%. The business had revenue of $41.24 million for the quarter, compared to analyst estimates of $39.54 million. During the same quarter in the prior year, the business posted ($0.30) EPS. As a group, equities analysts anticipate that Autolus Therapeutics will post -0.75 EPS for the current fiscal year.

Institutional Trading of Autolus Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of AUTL. Syncona Portfolio Ltd purchased a new stake in shares of Autolus Therapeutics in the 2nd quarter valued at $26,625,152. Cetera Investment Advisers raised its holdings in shares of Autolus Therapeutics by 2.7% during the first quarter. Cetera Investment Advisers now owns 1,129,074 shares of the company’s stock worth $1,558,000 after purchasing an additional 29,324 shares during the last quarter. Alphabet Inc. purchased a new position in shares of Autolus Therapeutics during the second quarter worth $1,117,000. Privium Fund Management B.V. raised its holdings in shares of Autolus Therapeutics by 29.2% during the third quarter. Privium Fund Management B.V. now owns 469,490 shares of the company’s stock worth $911,000 after purchasing an additional 106,060 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. raised its holdings in shares of Autolus Therapeutics by 2.5% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company’s stock worth $722,000 after purchasing an additional 11,197 shares during the last quarter. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Company Profile

(Get Free Report)

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing engineered T-cell therapies for cancer. Its treatments are designed to program a patient’s T cells to recognize and attack specific cancer cells, using the company’s proprietary cell-engineering technology. The company’s lead therapy, obecabtagene autoleucel (obe-cel), is marketed as Aucel and is approved in the United States and European Union for certain adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Recommended Stories

Analyst Recommendations for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.